The marker currently used to predict response to therapy is the combined positive score (CPS) for PD-L1 expression by the neoplastic cell (calculated as 100 times the number of PD-L1-positive cancer cells, lymphocytes, and macrophages, divided by the number of viable tumor cells). This evidence concerns the gene CD274 and neoplasm.